# A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

> **NCT03783000** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 425809
- **DRUG:** [C-14]-BI 425809

## Key facts

- **NCT ID:** NCT03783000
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-03-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783000, "A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03783000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*